Name: RVMDW Income Statement - Revolution Medicines Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

RVMDW - Revolution Medicines, Inc.

USD | NASDAQ | Healthcare

RVMDW Income Statement - Revolution Medicines Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19
Revenues
Revenues	-	-	-	-	-	0.0	0.0	0.0	0.0	0.7	0.0	3.8	7.0	15.3	3.4	9.1

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Revenues
Revenues	-	0.0	0.0	11.6	35.4	29.4	43.0	50.0	20.2
Cost of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	1,125.6	987.3	592.2	423.1	253.1	186.9	132.3	91.8	51.1
Selling General & Administrative	-	-	-	-
Operating Income
Operating Income	(1,386.8)	(1,182.4)	(689.5)	(487.2)	(258.3)	(188.0)	(110.7)	(54.1)	(40.3)
Non-Operating
Interest Income	85.3	90.7	86.9	47.5	9.2	0.9	2.2	2.2	0.8
Interest Expense	-	24.2	0.0	0.0	0.0
Tax & Net
Income Tax Expense	-	0.0	(0.8)	(3.5)	(0.4)	0.0	(0.4)	(4.4)	-
Net Income From Continuing Ops	(1,371.7)	(1,131.3)	(600.1)	(436.4)
Per Share
EPS Basic	(6.92)	(5.95)	(3.58)	(3.86)	(3.08)	(2.57)	(2.01)	-	-
EPS Diluted	(6.92)	(5.95)	(3.58)	(3.86)	(3.08)
Supplementary Data
EBITDA	(1,378.8)	(1,175.0)	(683.3)	(482.2)	(254.3)	(184.9)	(108.1)	(51.8)	(38.8)
EBIT	(1,386.8)	(1,182.4)	(689.5)	(487.2)	(258.3)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	344.0	294.9	262.5	224.1	205.7	187.5	151.8	134.9	118.0	148.5	107.7	98.0	68.9	66.1	69.5	61.0	56.5	53.7	46.5	45.9	40.9	37.0	34.9	32.9	27.5	27.5	23.0	20.1	21.2
Selling General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	101.3	66.7	52.8	40.6	35.0	28.8	24.0	21.7	22.8	32.2	15.5	14.6	13.2	10.9	10.4	10.2	9.0
Depreciation & Amortization	2.2	2.1	2.0	1.7	1.6	1.5	1.6	1.6	1.5	1.3	1.3	1.2	1.2	1.2	1.0	0.9
Amortization of Intangibles	0.0	0.0	0.3	0.3	0.3	0.2	0.3	0.3	0.3	0.2	0.3	0.3	0.3	0.2	0.3	0.3	0.3
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	445.2	361.6	315.3	264.7	240.8	216.3	175.7	156.6	140.9	180.7	123.2	112.6	82.2	77.0	79.9	71.2

Operating Income
Operating Income	(445.2)	(361.6)	(315.3)	(264.7)	(240.8)	(216.3)	(175.7)	(156.6)	(140.9)	(180.0)	(123.2)	(108.8)	(75.2)	(61.7)	(76.5)	(62.1)	(57.9)	(52.9)	(53.2)	(44.5)	(37.4)	(34.1)	(27.6)	(28.0)	(21.1)	(19.6)	(13.6)	(10.6)	(10.4)

Non-Operating
Interest Income	19.5	21.3	22.1	22.4	24.9	21.2	20.4	21.5	23.8	19.0	10.9	10.5	7.1	5.1	2.9	0.9	0.3	0.2	0.2	0.2	0.2	0.3	0.3	0.7	0.9	0.6	0.8	0.5	0.3
Interest Expense	12.2	-	11.4	-	0.0	-	0.0	-	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Income	(8.6)	(3.3)	10.1	16.9	27.3	21.0	19.4	23.4	24.9	18.8	10.9	10.5	7.1	5.1	2.9	0.9	0.3
Pre-Tax Income	(453.8)	(364.9)	(305.2)	(247.8)	(213.4)	(195.3)	(156.3)	(133.2)	(116.0)	(161.2)	(112.3)	(98.3)	(68.1)	(56.6)	(73.6)	(61.2)

Tax & Net
Income Tax Expense	-	-	-	-	-	(0.8)	0.0	0.0	0.0	0.3	(3.9)	0.0	0.0	(0.1)	(0.3)	0.0	0.0	0.0	0.0	0.0	0.0	-	-	(0.1)	(0.7)	-	-	-	-
Net Income From Continuing Ops	(453.8)	(364.9)	(305.2)	(247.8)	(213.4)	(194.6)	(156.3)	(133.2)	(116.0)	(161.5)	(108.4)	(98.3)	(68.1)	(56.5)	(73.3)	(61.2)	(57.6)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(453.8)	(364.9)	(305.2)	(247.8)	(213.4)	(194.6)	(156.3)	(133.2)	(116.0)	(161.5)	(108.4)	(98.3)	(68.1)	(56.5)	(73.3)	(61.2)	(57.6)
Net Income Attributable To Parent	(453.8)	(364.9)	(305.2)	(247.8)	(213.4)	(194.6)	(156.3)	(133.2)	(116.0)	(161.5)	(108.4)	(98.3)	(68.1)	(56.5)	(73.3)	(61.2)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(453.8)	(364.9)	(305.2)	(247.8)	(213.4)	(194.6)	(156.3)	(133.2)	(116.0)	(161.5)	(108.4)	(98.3)	(68.1)	(56.5)	(73.3)

Per Share
EPS Basic	(2.29)	-	(1.61)	(1.31)	(1.13)	-	(0.94)	(0.81)	(0.70)	-	(0.99)	(0.92)	(0.72)	-	(0.87)	(0.82)	(0.78)	-	(0.72)	(0.60)	-	-	-	-	-	-	-	-	-
EPS Diluted	(2.29)	-	(1.61)	(1.31)	(1.13)	-	(0.94)	(0.81)	(0.70)	-	(0.99)	(0.92)	(0.72)	-	(0.87)	(0.82)	(0.78)	-
Shares Basic	198.1	-	189.2	188.6	188.1	-	166.8	165.1	164.7	-	109.2	106.9	94.8	-	84.7	74.3	74.2	-
Shares Diluted	198.1	-	189.2	188.6	188.1	-	166.8	165.1	164.7	-	109.2	106.9	94.8	-	84.7	74.3	74.2	-

Supplementary Data
EBITDA	(443.0)	(359.5)	(313.3)	(263.0)	(239.2)	(214.8)	(174.1)	(155.0)	(139.4)	(178.7)	(121.9)	(107.6)	(74.0)	(60.5)	(75.5)	(61.2)	(57.0)	(52.1)	(52.4)	(43.7)	(36.7)	(33.4)	(26.9)	(27.4)	(20.5)	(18.9)	(13.0)	(10.1)	(9.9)
EBIT	(445.2)	(361.6)	(315.3)	(264.7)	(240.8)	(216.3)	(175.7)	(156.6)	(140.9)	(180.0)	(123.2)	(108.8)	(75.2)	(61.7)	(76.5)	(62.1)	(57.9)	(52.9)	(53.2)